0001193125-24-129357.txt : 20240502 0001193125-24-129357.hdr.sgml : 20240502 20240502160701 ACCESSION NUMBER: 0001193125-24-129357 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240430 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 24908193 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 8-K 1 d801460d8k.htm 8-K 8-K
false 0001817229 0001817229 2024-04-30 2024-04-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2024

 

 

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware   001-39979   81-1591163

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

100 Cambridgepark Drive

Suite 101

Cambridge, Massachusetts

   02140
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 655-6580

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   VOR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

Appointment of Fouad Namouni, M.D., as a Director

On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified. The Board also appointed Dr. Namouni to serve on the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).

Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines Corporation (“Blueprint”), a global biopharmaceutical company, since September 2020. Prior to Blueprint, Dr. Namouni served in various leadership roles at Bristol Myers Squibb Company (“BMS”) since 1999, most recently as Senior Vice President and Head of Oncology Development from August 2016 to April 2020 with the responsibility for driving product development plans across a portfolio of drug candidates. Previously, Dr. Namouni served as Head of Global Medical Affairs at BMS from September 2015 to September 2017 and Head of Development at BMS for OPDIVO® (nivolumab) and YERVOY® (ipilimumab) from January 2011 to September 2015. Dr. Namouni previously served as a member of the board of directors of Aprea Therapeutics Inc. from June 2020 to May 2022. Dr. Namouni has more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. He holds an M.D. from the University of Annaba Medical School in Algeria and a Pediatrics degree from Université Rene Descartes in Paris, France. Additionally, Dr. Namouni received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France. The Company believes that Dr. Namouni is qualified to serve on the Board due to his experience in oncology and cancer immunotherapy drug development and his service in leadership roles and as a director of other biotechnology companies.

In connection with his service as a director, Dr. Namouni will receive the Company’s standard non-employee director cash and equity compensation under its Non-Employee Directors’ Compensation Policy, which is filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2023. Pursuant to the Non-Employee Directors’ Compensation Policy, Dr. Namouni will receive a cash retainer fee of $40,000 for service as a director and $4,000 for service as a member of the Nominating Committee, payable in equal quarterly installments in arrears on the last day of each fiscal quarter, in each case pro-rated based on days served in the applicable fiscal quarter. In addition, Dr. Namouni received a stock option to purchase 60,000 shares of the Company’s common stock on the date of his appointment to the Board and will be eligible to receive a stock option to purchase 30,000 shares of the Company’s common stock on the date of each annual stockholder meeting of the Company, beginning with the 2024 stockholder meeting.

Dr. Namouni also entered into an indemnification agreement with the Company in the form previously approved by the Board and filed with the SEC as Exhibit 10.8 to the Company’s Registration Statement on Form S-1 on January 15, 2021.

There is no arrangement or understanding between Dr. Namouni and any other person pursuant to which Dr. Namouni was appointed as a member of the Board, and Dr. Namouni has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 7.01

Regulation FD Disclosure.

On May 2, 2024, the Company issued a press release announcing the appointment of Dr. Namouni to the Board, a copy of which is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
No.		   

Description

99.1    Press Release, dated May 2, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 2, 2024     Vor Biopharma Inc.
    By:  

/s/ Robert Ang

    Name:   Robert Ang
    Title:   Chief Executive Officer
 EX-99.1 2 d801460dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 2, 2024 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio’s Board.

In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company’s fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in clinical development, regulatory affairs, and medical affairs within the biotechnology and pharmaceutical industries, Dr. Namouni’s insights and strategic guidance will be invaluable to Vor Bio as it continues to advance its novel approach to curing acute myeloid leukemia.

“We are thrilled to welcome Dr. Namouni to Vor Bio’s Board of Directors,” said Dr. Robert Ang, President and CEO of Vor Bio. “His deep oncology development experience will be invaluable as Vor Bio navigates toward late phase trials and beyond.” Matthew R. Patterson, Chairman of Vor Bio, added, “Dr. Namouni’s decades of industry experience in both pharmaceutical and biotechnology research and development complements and strengthens the diverse perspectives on Vor’s Board and I look forward to working closely with him.”

Dr. Namouni has over 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to his current role as President of Research & Development, at Blueprint Medicines, Dr. Namouni held multiple senior leadership positions at Bristol-Myers Squibb where he played a pivotal role in the development and commercialization of groundbreaking oncology therapies including Opdivo® and Yervoy®. Throughout his career, Dr. Namouni has been dedicated to driving scientific innovation and improving patient outcomes.

“With innovative science, sound strategy and strong leadership, Vor Bio is poised to translate advances in cell and genome engineering into potential cures for acute myeloid leukemia and other blood cancers with high medical needs,” said Dr. Namouni. “I am pleased to join the Board and look forward to contributing my knowledge and experience in oncology and hematology drug development as the company continues to make progress in the clinic and work toward bringing important new medicines to patients.”

Dr. Namouni holds an M.D. from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

LOGO

 

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of its therapeutic approach to cure AML and other blood cancers, the ability of the Vor Bio platform to address the complexities of treating blood cancers, the potential of engineered hematopoietic stem cells to enable targeted therapies in the post-transplant setting, and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio’s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Contact:

Investors & Media

Sarah Spencer

+1 857-242-6076

sspencer@vorbio.com

EX-101.SCH 3 vor-20240430.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vor-20240430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 vor-20240430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g801460dsp005.jpg GRAPHIC begin 644 g801460dsp005.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 30, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001817229
Document Type 8-K
Document Period End Date Apr. 30, 2024
Entity Registrant Name Vor Biopharma Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39979
Entity Tax Identification Number 81-1591163
Entity Address, Address Line One 100 Cambridgepark
Entity Address, Address Line Two Drive
Entity Address, Address Line Three Suite 101
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 655-6580
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol VOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d801460d8k.htm vor-20240430.xsd vor-20240430_lab.xml vor-20240430_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d801460d8k.htm": { "nsprefix": "vor", "nsuri": "http://vorbiopharma.com/20240430", "dts": { "inline": { "local": [ "d801460d8k.htm" ] }, "schema": { "local": [ "vor-20240430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "vor-20240430_lab.xml" ] }, "presentationLink": { "local": [ "vor-20240430_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-30_to_2024-04-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d801460d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-30_to_2024-04-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d801460d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vorbiopharma.com//20240430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-129357-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-129357-xbrl.zip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end XML 18 d801460d8k_htm.xml IDEA: XBRL DOCUMENT 0001817229 2024-04-30 2024-04-30 false 0001817229 8-K 2024-04-30 Vor Biopharma Inc. DE 001-39979 81-1591163 100 Cambridgepark Drive Suite 101 Cambridge MA 02140 (617) 655-6580 false false false false Common Stock, $0.0001 par value per share VOR NASDAQ true false